Method of inhibiting mutant C-kit

• US 9,480,683 B2
• Filed: 09/13/2013
• Issued: 11/01/2016
• Est. Priority Date: 09/26/2012
• Status: Active Grant

• Current Assignee: AROG Pharmaceuticals LLC
• Original Assignee: AROG Pharmaceuticals LLC
• Inventors: Jain, Vinay K.
• Primary Examiner(s): Wang, Shengjun
• Application Number:
  US14/026,886
• Publication Number:
  US 20140088147A1
• Time in Patent Office: 1,145 Days
• Field of Search: 514/314
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4709 Non-condensed quinolines and containing further heterocyclic rings
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention includes a method of reducing or inhibiting the kinase activity of C-KIT mutant tyrosine kinase activity in a cell or a subject, and the use of such compound for treating mutant C-KIT driven cell proliferative disorder(s) in a subject related to using a compound of the present invention:

or pharmaceutically acceptable salt thereof.

Claims

1. A method of inhibiting or reducing mutant C-KIT tyrosine kinase activity or expression in a subject having or suspected of having a proliferative disease positive for a constitutively active mutant C-KIT, comprised of identifying the subject having a proliferative disease positive for a constitutively active mutant C-KIT, wherein the C-KIT mutant is at least one of C-KIT D816, D816F, D816H, D816N, D816Y and D816V, and administering to the subject a therapeutically effective amount of the compound of Formula I:

2. The method of claim 1, wherein the proliferative disease is selected from at least one of mastocytosis, acute myeloid leukemia, gastrointestinal stromal tumors, sinonasal NK/T-cell lymphoma, seminomas, dysgerminomas, melanomas, and thymic carcinomas.

3. The method of claim 1, wherein the therapeutically effective amount is between about 15 mg/day to about 500 mg/day, between about 25 mg/day to about 450 mg/day, between about 50 mg/day to about 400 mg/day, between about 100 mg/day to about 350 mg/day, between about 150 mg/day to about 300 mg/day, between about 200 mg/day to about 250 mg/day, about 15 mg/day, about 25 mg/day, about 50 mg/day, about 75 mg/day, about 100 mg/day, about 150 mg/day, about 200 mg/day, about 250 mg/day, about 300 mg/day, about 400 mg/day, about 450 mg/day, or about 500 mg per day.

4. The method of claim 1, wherein the compound is administered at least one of continuously, intermittently, systemically, or locally.

5. The method of claim 1, wherein the compound is administered orally, intravenously, or intraperitoneally.

6. The method of claim 1, wherein the Crenolanib is Crenolanib Besylate, Crenolanib Phosphate, Crenolanib Lactate, Crenolanib Hydrochloride, Crenolanib Citrate, Crenolanib Acetate, Crenolanib Toluenesulphonate or Crenolanib Succinate.

7. The method of claim 1, wherein the therapeutically effective amount of compound is administered up to three times or more a day for as long as the subject is in need of treatment for a proliferative disease positive for a constitutively active mutant C-KIT.

8. The method of claim 1, wherein the compound is provided at least one of sequentially or concomitantly with another pharmaceutical agent in a newly diagnosed proliferative disease subject to maintain remission, or in a relapsed/refractory proliferative disease subject.

9. The method of claim 1, wherein compound is provided as a single agent or in combination with another pharmaceutical agent in a newly diagnosed proliferative disease subject, to maintain remission, or in a relapsed/refractory proliferative disease subject.

10. The method of claim 1, wherein the compound is provided as a single agent or in combination with another pharmaceutical agent in a newly diagnosed proliferative disease pediatric subject, to maintain remission, or a relapsed/refractory proliferative disease pediatric subject.

11. The method of claim 1, further comprising the step of determining if the subject is relapsed/refractory to at least one prior therapy.

22. The method of claim 11, wherein the prior therapy is selected from at least one of interferon alpha, 2-chlorodeoxyadenosine or Imatinib mesylate.

12. A method for treating a subject suffering from a proliferative disease positive for a constitutively active mutant C-KIT comprising:

identifying the subject suffering from the proliferative disease positive for a constitutively active mutant C-KIT wherein the C-KIT mutant is at least one of C-KIT D816, D816F, D816H, D816N, D816Y and D816V, and, wherein the proliferative disease is selected from at least one of a mastocytosis, acute myeloid leukemia, gastrointestinal stromal tumors, sinonasal NK/T-cell lymphoma, seminomas, dysgerminomas, melanomas, or thymic carcinomas, and wherein the proliferative disease is characterized by mutant C-KIT receptor tyrosine kinase activity, and

administering to the subject in need of such treatment a therapeutically effective amount of Crenolanib or a salt thereof.

13. The method of claim 12, wherein the compound is administered orally, intravenously, or intraperitoneally.

14. The method of claim 12, wherein the Crenolanib is Crenolanib Besylate, Crenolanib Phosphate, Crenolanib Lactate, Crenolanib Hydrochloride, Crenolanib Citrate, Crenolanib Acetate, Crenolanib Toluenesulphonate or Crenolanib Succinate.

15. The method of claim 12, wherein the therapeutically effective amount of the Crenolanib is administered up to three times or more a day for as long as the subject is in need of treatment for proliferative disease positive for a constitutively active mutant C-KIT.

16. The method of claim 12, wherein the Crenolanib is provided at least one of sequentially or concomitantly with another pharmaceutical agent in a newly diagnosed proliferative disease subject, to maintain remission, or in a relapsed/refractory proliferative disease subject.

17. The method of claim 12, wherein the Crenolanib is provided as a single agent or in combination with another pharmaceutical agent for treatment of a pediatric subject with the proliferative disease.

18. The method of claim 12, wherein the Crenolanib is provided as a single agent to at least one of post chemotherapeutic or targeted therapy in newly diagnosed proliferative disease.

19. The method of claim 12, wherein the Crenolanib is provided as a single agent in treatment of the subject, wherein the proliferative disease is either refractory to, or has relapsed after, treatment with another chemotherapeutic or targeted therapy.

20. The method of claim 12, wherein the subject is relapsed/refractory to at least one prior therapy.

21. The method of claim 12, further comprising the step of determining whether the subject has a cancer caused by uncontrolled C-KIT tyrosine kinase activity or expression.

23. The method of claim 20, wherein the prior therapy is selected from at least one of interferon alpha, 2-chlorodeoxyadenosine or Imatinib mesylate.

24. A method of inhibiting or reducing mutant C-KIT tyrosine kinase activity or expression in a subject having a proliferative disease positive for a constitutively active mutant

C-KIT, which comprises administering to the subject a therapeutically effective amount of the compound of Formula I:

25. A method for treating a subject suffering from a proliferative disease positive for a constitutively active mutant C-KIT comprising:

obtaining a sample from a subject suspected of having a proliferative disease selected from at least one of a mastocytosis, acute myeloid leukemia, gastrointestinal stromal tumor, sinonasal NK/T-cell lymphoma, seminoma, dysgerminoma, melanoma, or thymic carcinoma;

determining if the proliferative disease is positive for a constitutively active mutant C-KIT; and

administering to the subject in need of such treatment a therapeutically effective amount of Crenolanib or a salt thereof sufficient to treat the proliferative disease that is positive for a constitutively active mutant C-KIT, wherein the C-KIT mutant is at least one of C-KIT D816, D816F, D816H, D816N, D816Y and D816V.